Beranda › Penyakit Hati Steatotik
Uji klinis Penyakit Hati Steatotik yang merekrut di AS
65 studi untuk Penyakit Hati Steatotik merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- San Antonio, TX17 studi
- New York City, NY16 studi
- Miami, FL16 studi
- San Diego, CA14 studi
- Austin, TX13 studi
- Houston, TX13 studi
- Richmond, VA12 studi
- Tucson, AZ10 studi
- Chandler, AZ10 studi
- Orlando, FL9 studi
- Hialeah, FL9 studi
- St. Louis, MO9 studi
- Dallas, TX9 studi
- Durham, NC8 studi
- Dayton, OH8 studi
- Little Rock, AR8 studi
- Los Angeles, CA8 studi
- New Orleans, LA8 studi
- Pasadena, CA8 studi
- Ocala, FL8 studi
- Rochester, MN8 studi
- Akron, OH7 studi
- Seattle, WA7 studi
- Washington, DC7 studi
- Parma, OH7 studi
- Lancaster, CA7 studi
- Brownsville, TX7 studi
- Topeka, KS7 studi
- Las Vegas, NV7 studi
- Round Rock, TX7 studi
- Chicago, IL6 studi
- Sugar Land, TX6 studi
- Cape Coral, FL6 studi
- Sarasota, FL6 studi
- Sandy Springs, GA6 studi
- Peoria, AZ6 studi
- Indianapolis, IN6 studi
- Fort Worth, TX6 studi
- Fayetteville, NC6 studi
- Arlington, TX6 studi
Berdasarkan negara bagian
- Alabama4 studi
- Arizona14 studi
- Arkansas8 studi
- California22 studi
- Colorado6 studi
- Connecticut5 studi
- Florida20 studi
- Georgia8 studi
- Illinois6 studi
- Indiana9 studi
- Iowa4 studi
- Kansas7 studi
- Kentucky4 studi
- Louisiana11 studi
- Maryland8 studi
- Massachusetts9 studi
- Michigan8 studi
- Minnesota9 studi
- Mississippi5 studi
- Missouri14 studi
- Nevada7 studi
- New Jersey6 studi
- New Mexico3 studi
- New York17 studi
- North Carolina13 studi
- Ohio15 studi
- Pennsylvania5 studi
- Rhode Island3 studi
- South Carolina5 studi
- Tennessee7 studi
- Texas20 studi
- Utah5 studi
- Virginia14 studi
- Washington7 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Menerima pesertaFase 3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07704892A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Menerima pesertaFase 3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07701993A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07527910Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05832229Early Tracking of Childhood Health Determinants (ETCHED) Study
Menerima pesertaStudi observasionalSukarelawan sehat diterima
1 Day – 99 Years · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT03481829A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07165028Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
Menerima pesertaFase 2
Usia 5 hingga 16 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06133101A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Menerima pesertaFase 3
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Menerima pesertaFase 3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07221188Fully Automated High-Throughput Quantitative MRI of the Liver
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 7 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT05294471A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Menerima pesertaFase 3
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Menerima pesertaFase 3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06419374Human Models of Selective Insulin Resistance: Alpelisib, Part I
Menerima pesertaFase 1Sukarelawan sehat diterima
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT06354088Quantifying Hepatic Mitochondrial Fluxes in Humans
Menerima pesertaFase 4
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT05305287InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Semua usia · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT05463796Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis
Menerima pesertaSukarelawan sehat diterima
Usia 25 hingga 55 · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT06993454Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Menerima pesertaFase 2Sukarelawan sehat diterima
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT03884075Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
Menerima pesertaSukarelawan sehat diterima
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06335771Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06571474Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease
Menerima peserta
Usia 30 hingga 70 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT07646197A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
Menerima pesertaFase 2
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT06613698Fibrosis Lessens After Metabolic Surgery
Menerima pesertaFase 4Sukarelawan sehat diterima
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT06374875Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
Menerima pesertaStudi observasional
Usia 12 hingga 18 · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT04634643Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.